title: Phase II trial of esorubicin in advanced renal carcinoma. Clinical Screening Group of the EROTC.
authors.forename: P
authors.initials: P
authors.lastname: Hurteloup
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: H
authors.initials: H
authors.lastname: Roche
authors.forename: B
authors.initials: B
authors.lastname: Chevallier
authors.forename: P
authors.initials: P
authors.lastname: Cappelaere
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbece
authors.forename: M
authors.initials: M
authors.lastname: Hayat
authors.forename: J P
authors.initials: JP
authors.lastname: Armand
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C030851:esorubicin